How Patients Can Access Sangamo Therapeutics' Clinical Trials and Resources

Sangamo Therapeutics provides patient-facing information through three main channels: a Clinical Trials section, an Expanded Access Policy, and a Patient Focus area with stories and resources. You can use these to learn which programs are recruiting, what Sangamo's stated position is on access outside trials, and where to find education and advocacy materials. Note that the site does not publish enrollment forms, eligibility screeners, or contact emails for trial participation—those steps run through the clinical sites themselves, so the practical path is to identify a program, then work with a study site or your physician.

Start With the Clinical Programs Listed

Sangamo's site organizes its patient-relevant work under Programs → Clinical Programs. The named clinical programs are:

• Small Fiber Neuropathy (SFN)
• Fabry Disease
• Hemophilia A

These are the areas where the company says it has clinical-stage activity. If your condition is not on this list, the site does not indicate an active clinical program you can join, though Sangamo also lists broader therapeutic applications in Neurology and Oncology under its technology platforms.

A practical first step: check whether your diagnosis matches one of the three named programs before spending time on the rest of the site.

Find Trial Information and Participation Paths

The Clinical Trials section (linked from the main navigation and repeated in the Programs menu) is the entry point for participation information. On the site, this section sits alongside Collaborations & Partners, which matters because Sangamo runs programs with partners—so the trial you want may be listed under a partner's name or conducted at sites the partner manages.

What the site does and does not give you:

Because Sangamo does not publish a trial locator with site addresses or phone numbers, the workable approach is to take the program name (for example, "Fabry Disease" or "Hemophilia A") to a public trial registry or to your treating physician, who can check whether a Sangamo-sponsored or partner-sponsored study is recruiting near you. Your physician is also the person who can speak to whether you might meet a study's entry criteria—Sangamo's site does not list those criteria.

Understand the Expanded Access Policy

Sangamo publishes an Expanded Access Policy under Patients → Our Commitment. Expanded access (sometimes called compassionate use) is the route for getting an investigational therapy outside a clinical trial, typically when a patient cannot enroll in a trial and has a serious condition.

Two things to keep straight:

• The existence of a policy page means Sangamo has a stated position on expanded access. It does not mean access is granted on request, and the site does not present it as a general pathway.
• Expanded access decisions are made case by case and generally require your physician to initiate the request. The site does not provide a patient-facing application.

If you are asking about expanded access, the realistic sequence is: your physician reviews the policy, contacts Sangamo on your behalf, and you continue any trial-eligible options in parallel rather than instead.

Use the Patient Focus Resources

Under Patients, the site groups several resource types:

• Our Commitment and Bioethics — statements of how Sangamo frames its responsibilities to patients.
• Expanded Access Policy — as above.
• Patient Stories — first-person accounts from named individuals: Bryan, Lori, Matt, and Elizabeth (Fabry Disease); Israel and Miles (Hemophilia A); Trevor (Prion Disease); and Sharron (a renal transplant patient).
• Patient Focus Resources — education and organizations, aimed at patients and advocacy groups.

The patient stories are useful for understanding what living with these conditions and participating in research has looked like for specific people. They are personal narratives, not clinical evidence, and the site does not present them as outcome data. Read them for context on the patient experience, not as a prediction of how a therapy will work.

The Education and Organizations links under Patient Focus Resources are the most portable part of the site: they point toward disease education and advocacy groups that often maintain their own trial-matching help, which can fill the gap Sangamo's site leaves.

A Note on Company Status

The site's news area references a Chapter 11 reorganization and asset sales, with additional information available through Sangamo's noticing agent at veritaglobal.net/SangamoTherapeutics, and a notice about selecting successful bidders following a competitive asset auction. If you are planning to pursue a trial or expanded access request, check the latest news releases and the noticing agent page first—program status, sponsorship, and who to contact can change during a reorganization, and the site's program pages may not reflect the most current ownership or continuation of a given program.

Practical Sequence

1. Confirm your condition matches a listed clinical program (SFN, Fabry Disease, or Hemophilia A).
2. Read the Clinical Trials section and the relevant program page for the program name.
3. Take that program name to your physician and to a public trial registry to find recruiting sites and eligibility criteria.
4. If a trial is not possible, read the Expanded Access Policy and ask your physician whether a request is appropriate.
5. Use Patient Stories and Patient Focus Resources for context and for advocacy organizations that offer independent navigation help.
6. Check News Releases and the noticing agent page for current status before acting on any program.